Literature DB >> 26902127

Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect.

Jack L Arbiser1, Michael Y Bonner2.   

Abstract

Neel et al. have demonstrated that seborrheic keratosis, the most common of all skin tumors, is dependent on acutely transforming retrovirus AKT8 in rodent T-cell lymphoma signaling. The authors found that these lesions are hypersensitive to Akt inhibitors which bind to the ATP binding site of Akt. Cutaneous squamous cell carcinoma is resistant to Akt inhibitors. The implications of this study are not limited to seborrheic keratosis. The presence of wild type p53 (seborrheic keratosis) or mutant p53 (cutaneous squamous cell carcinoma) appears to dictate whether a lesion is sensitive to Akt inhibition or not.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26902127      PMCID: PMC5925755          DOI: 10.1016/j.jid.2015.12.019

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

2.  Sustained Akt Activity Is Required to Maintain Cell Viability in Seborrheic Keratosis, a Benign Epithelial Tumor.

Authors:  Victor A Neel; Kristina Todorova; Jun Wang; Eunjeong Kwon; Minjeong Kang; Qingsong Liu; Nathanael Gray; Sam W Lee; Anna Mandinova
Journal:  J Invest Dermatol       Date:  2015-12-29       Impact factor: 8.551

3.  Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis.

Authors:  Jack L Arbiser; Baskaran Govindarajan; Xianhe Bai; Hiroaki Onda; Andrius Kazlauskas; So Dug Lim; Mahul B Amin; Lena Claesson-Welsh
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

Review 4.  Targeting NADPH oxidases for the treatment of cancer and inflammation.

Authors:  Michael Y Bonner; Jack L Arbiser
Journal:  Cell Mol Life Sci       Date:  2012-05-13       Impact factor: 9.261

5.  A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.

Authors:  Anna Mandinova; Vihren Kolev; Victor Neel; Bing Hu; Wesley Stonely; Jocelyn Lieb; Xunwei Wu; Claudia Colli; Rong Han; Michael J Pazin; Mike Pazin; Paola Ostano; Reinhard Dummer; Janice L Brissette; G Paolo Dotto
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

6.  PIK3CA is implicated as an oncogene in ovarian cancer.

Authors:  L Shayesteh; Y Lu; W L Kuo; R Baldocchi; T Godfrey; C Collins; D Pinkel; B Powell; G B Mills; J W Gray
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

7.  Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

Authors:  Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

8.  Solenopsin A and analogs exhibit ceramide-like biological activity.

Authors:  Isabella Karlsson; Xin Zhou; Raquela Thomas; Allorie T Smith; Michael Y Bonner; Pooja Bakshi; Ajay K Banga; J Phillip Bowen; Ghassan Qabaja; Shavon L Ford; Matthew D Ballard; Kimberly S Petersen; Xuechen Li; Guangping Chen; Besim Ogretmen; Jin Zhang; E Blake Watkins; Rebecca S Arnold; Jack L Arbiser
Journal:  Vasc Cell       Date:  2015-05-08
  8 in total
  1 in total

1.  Genetic alterations in seborrheic keratoses.

Authors:  Barbara Heidenreich; Evygenia Denisova; Sivaramakrishna Rachakonda; Onofre Sanmartin; Timo Dereani; Ismail Hosen; Eduardo Nagore; Rajiv Kumar
Journal:  Oncotarget       Date:  2017-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.